NPFPro

We are working toward a world free of #psoriaticdisease by supporting research, education, and advocating for the needs of our community. #NPFPro

[NPFPro @NPFPro]

Join our reimagined NPF Professional Membership program for trusted clinical resources, patient ed tools, networking, and to elevate your visibility in the field.
Be part of a community dedicated to advancing psoriatic disease care and research: https://t.co/XJgrvw4X1j

[NPFPro @NPFPro]

Thanks for posting this and sharing the link to our NPF Medical Board primer on GLP-1s and psoriasis, @EricTopol

The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review | Dermatology | JAMA Dermatology | JAMA Network

[Eric Topol @EricTopol]

Expanded benefits reported today for GLP-1 therapy @JAMADerm
Extragenital lichen sclerosus
https://t.co/C45PMf6yVx
Potential for psoriasis, a review of evidence
https://t.co/DYToF3p3db

[NPFPro @NPFPro]

NPF Grant Applications are OPEN! Don’t miss out on these opportunities! We have opportunities available ranging from early-career researchers, to discovery or translational research, and more! Learn more today: https://t.co/e5bCKSqdG2.

[NPFPro @NPFPro]

Happening now, Hall F1! The NPF was successful in helping establish a PsA component to the fNIH AMP/AIM program. In fact, may be better described as “wildly successful.” The possibilities with spatial mutlti-omics seem nearly endless (Abstract 2233: https://t.co/egPtzA5f9k).

[NPFPro @NPFPro]

At 10:15! NPF supported research that our CSMO consistently calls “jaw dropping.” Join Dr. Garcia-Hernandez’s presentation on creating mouse models of human PsD endotypes, #1753: Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model in W190A-B. #ACR25

[NPFPro @NPFPro]

Inspiring stories from our #psoriaticarthritis community are everywhere! Hear former NPF Board member, Kathleen Gallant, share her journey at 8:45 am in W192A-C. #ACR25

[NPFPro @NPFPro]

Explore sex differences in psoriatic disease. #ACR25 posters 1714: Perimenopause links to higher psoriatic arthritis activity; 0873: Deucravacitinib’s impact on sex-specific proteomic profiles in active psoriatic arthritis. Both presented TODAY by Lihi Eder, MD, PhD

[NPFPro @NPFPro]

While you’re thinking about your recruitment messages at Dr. Kearney’s Poster, did you know that the NPF MyStudies program (https://t.co/Gwo58D3ko4) can help find patients interested in clinical research and located in your community? #ACR25

[NPFPro @NPFPro]

NPF alums' #ACR25 poster presentations getting to the heart of systemic inflammation consequences. See what we did there? Abstract 0522 from Lihi Eder on arrhythmias in PsA and 0546 on comorbidity groupings from Dr. Karmacharya are a great place to learn more. Now-Hall F1

[NPFPro @NPFPro]

1030am, Hall F1! NPF is proud to collaborate with CorEvitas on psoriatic disease registries. Check out real-world data about persistence of therapeutic agents (Abstracts 0362, 0579, 0578), & the therapeutic benefit of TYK2 on PsA (0455). #ACR25

[NPFPro @NPFPro]

The growing field of biomarkers for PsA is revolutionary. Take a look at what’s possible in today’s clinical trials - Abstract 0590 features technologies aligned with the NPF’s investment in PsA diagnostics. Presentations start at 10:30am, Hall F1 #ACR25

[NPFPro @NPFPro]

Tremfya® has just been approved for the treatment of children who are 6 years and older, and live with moderate to severe plaque psoriasis. This new indication marks the first and only (IL) - 23 inhibitor available to the pediatric population. Learn more🔗https://t.co/R2xy1HAAAt

[NPFPro @NPFPro]

Happy #InternationalPodcastDay! We are proud to bring you stories, #treatment updates, guidance on managing #psoriaticdisease, and so much more with #PsoundBytesCME for providers treating psoriatic disease.

Listen and learn: https://t.co/JOM6Hjy2D5

[NPFPro @NPFPro]

You can read more about our grants here: https://t.co/HqC48NbmpB

[NPFPro @NPFPro]

TODAY is Generalized Pustular Psoriasis (GPP) Awareness Day, a day to shine a light on a rare and serious form of psoriasis. Help spread the word!

Learn more and explore our full GPP Resource Center ⬇️ https://t.co/E9g4VMEEKx

[Healio Dermatology @HealioDerm]

This year’s @NPF Commit to Cure gala raised more than 🎉$1.5 million🎉 for psoriatic research, breaking past fundraising records.

Honorees this year included @GoHealio | Dermatology Chief Medical Editor Joel M. Gelfand, MD.

Read more ⬇️
https://t.co/kbOsmhwp83
@leahmcchoward

[NPFPro @NPFPro]

New Psound Bytes Pro episode is out! Hear from Dr. Mark Lebwohl, M.D. and Dr. Jason Hawkes, M.D., M.S. discuss the intersection of obesity, psoriasis, and GLP-1s.

https://t.co/AjikJF2Q0I

[NPFPro @NPFPro]

It is estimated that generalized pustular #psoriasis affects 3% of people living with PsO. However, data have shown that patients report GPP symptoms, even when GPP #flares are under control.

Read more: https://t.co/iqzCeSe8Ki

[Health Affairs @Health_Affairs]

In their new Forefront article, @elisaoehrlein, Leah McCormick Howard, Joe Vandigo, and @Kim_Westrich from @NHCouncil and @NPF discuss how by, elevating patient perspectives from an afterthought to a core part of the process, payers can create a system that aligns more closely with patients’ needs, ultimately improving care and fostering greater trust. https://t.co/7ZvTQ2x21B